Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03, Bloomberg Earnings reports.
Shares of Bellerophon Therapeutics (NASDAQ:BLPH) traded up 2.65% on Friday, reaching $1.16. The company’s stock had a trading volume of 186,718 shares. The company’s market capitalization is $41.19 million. The company’s 50-day moving average is $1.32 and its 200 day moving average is $1.32. Bellerophon Therapeutics has a 12-month low of $0.43 and a 12-month high of $1.98.
Several research analysts have commented on the company. Zacks Investment Research downgraded Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. ValuEngine downgraded Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 10th.
An institutional investor recently raised its position in Bellerophon Therapeutics stock. Vanguard Group Inc. increased its position in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) by 52.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 612,641 shares of the biotechnology company’s stock after buying an additional 211,111 shares during the period. Vanguard Group Inc. owned approximately 1.86% of Bellerophon Therapeutics worth $821,000 at the end of the most recent reporting period. 42.11% of the stock is currently owned by hedge funds and other institutional investors.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.